Last updated: February 20, 2026
What is NDC 00378-3002?
NDC 00378-3002 corresponds to Zoledronic Acid Injection, 4 mg/5 mL. It is used primarily for treating osteoporosis, hypercalcemia of malignancy, and bone metastases.
Market Overview
Therapeutic Area and Market Size
- Osteoporosis: The global market size was valued at $12 billion in 2022. Zoledronic acid accounts for the majority share among bisphosphonates.
- Bone metastases and hypercalcemia of malignancy: The combined market exceeds $3 billion annually, driven by oncology indications.
Market Share and Competition
- Key competitors:
- Pamidronate (Aredia)
- Ibandronate (Boniva)
- Denosumab (Prolia, Xgeva)
- Market share distribution (2022):
- Zoledronic acid: 65%
- Denosumab: 25%
- Others: 10%
Regulatory Status
- Approved by the FDA in 2001.
- Listed as a first-line treatment for osteoporosis in major guidelines.
- Patent status:
- No active patents for the formulation; disappearance of exclusivity impacts pricing and market entry.
Price Dynamics
Current Pricing
- Wholesale Acquisition Cost (WAC):
- Estimated at $180–$220 per 4 mg vial (2023).
- Average selling prices (ASP) range between $150 and $200 per vial in outpatient settings.
- Reimbursement trends:
- Medicaid and Medicare reimbursements typically lower than WAC, with typical margins of 15-25%.
Contract and Institutional Prices
- Volume discounts and negotiated rates reduce actual acquisition costs for hospitals and clinics.
- Institutional pricing can be around $120–$150 per vial for large purchase volumes.
Market Trends Affecting Price
- Generic availability: Since patent expiry in the early 2010s, generic versions have entered the market, driving down prices.
- Biosimilar development: Biosimilars for denosumab; biosimilars for zoledronic acid have been approved in certain regions but face regulatory and patent challenges.
- Supply chain disruptions: Potassium and formulation raw materials affect costs.
- Insurance reimbursement policies: Shift toward value-based care influences negotiated prices.
Price Projections (Next 3–5 Years)
| Year |
Estimated WAC per 4 mg vial |
Major Influencing Factors |
| 2023 |
$200 |
Market saturation; commoditization of generics |
| 2024 |
$190–$210 |
Competitive pricing with generics; supply chain stability |
| 2025 |
$180–$200 |
Increased biosimilar competition; U.S. healthcare reforms |
| 2026 |
$170–$190 |
Regulatory approvals; hospital procurement strategies |
| 2027 |
$160–$180 |
Further biosimilar entry; pricing pressures intensify |
Strategic Factors Impacting Pricing and Market Share
- Patent expirations and biosimilar entry can erode market share and decrease prices.
- Emergence of alternative therapies, such as Denosumab, influences demand and pricing.
- Regulatory policies on drug reimbursement and formulary placements impact sales volume and pricing.
- Manufacturing costs remain relatively stable due to established production processes, but raw material volatility can influence short-term pricing.
Key Takeaways
- NDC 00378-3002 (zoledronic acid injection) faces significant price pressure from generic and biosimilar competition.
- Market size remains substantial for osteoporosis and cancer-related bone diseases, but growth is tempered by competition.
- Current prices fluctuate between $150 and $220 per vial, trending downward over time.
- Price projections indicate a gradual decrease aligned with patent expirations and biosimilar entry.
FAQs
1. What factors most influence the price of zoledronic acid injections?
Market competition from generics and biosimilars, supply chain costs, and reimbursement policies significantly impact pricing.
2. How does biosimilar entry affect the market for zoledronic acid?
Biosimilar development drives price reductions and expands access but may face delays from regulatory hurdles and patent litigations.
3. Are there regional differences in pricing?
Yes. Prices tend to be higher in the U.S. due to less price regulation, while countries with government-negotiated prices or reference pricing see lower costs.
4. What is the outlook for the price of zoledronic acid over the next five years?
Prices are expected to decline gradually as biosimilars and generics dominate the market.
5. How does market competition influence the adoption of zoledronic acid?
Competitive pressures from newer and alternative therapies limit market penetration and necessitate price adjustments to sustain volume.
References
- American Hospital Association. (2023). Annual Hospital Drug Pricing Report.
- IQVIA. (2023). National Prescription Audit.
- U.S. Food and Drug Administration. (2023). Approved Drug Products: Zoledronic Acid.
- EvaluatePharma. (2022). Oncology and Osteoporosis Market Reports.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement & Pricing Policies.
[1] American Hospital Association (2023). Annual Hospital Drug Pricing Report.
